Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aquestive Therapeutics Inc.

2.51
+0.01000.40%
Post-market: 2.520.0108+0.43%19:25 EDT
Volume:1.11M
Turnover:2.78M
Market Cap:248.17M
PE:-4.93
High:2.58
Open:2.50
Low:2.47
Close:2.50
Loading ...

Aquestive Therapeutics Receives FDA 'Positive Feedback' for Anaphylm Sublingual Film

MT Newswires Live
·
02 Dec 2024

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms Nda Submission Guidance for Anaphylm™ (Epinephrine) Sublingual Film

THOMSON REUTERS
·
02 Dec 2024

Aquestive Therapeutics Inc -Confirms No Additional Adult Clinical Trials Are Necessary Prior to Nda Submission

THOMSON REUTERS
·
02 Dec 2024

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

GlobeNewswire
·
02 Dec 2024

Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?

Insider Monkey
·
16 Nov 2024

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
12 Nov 2024

Aquestive Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
06 Nov 2024

Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...

GuruFocus.com
·
06 Nov 2024

Aquestive Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
05 Nov 2024

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
05 Nov 2024

Aquestive Therapeutics Q3 EPS $(0.13), Inline, Sales $13.54M Beat $12.68M Estimate

Benzinga
·
05 Nov 2024

Aquestive Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
05 Nov 2024

Stock Track | Aquestive Therapeutics Plunges After-Hours on Wider Q3 Loss, Higher Expenses

Stock Track
·
05 Nov 2024

Aquestive Therapeutics: Reaffirms Cash Runway Into 2026

THOMSON REUTERS
·
05 Nov 2024

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
05 Nov 2024

Aquestive Therapeutics Outlook Full-Year Total Revenue $57 Mln to $60 Mln

THOMSON REUTERS
·
05 Nov 2024

Aquestive Therapeutics Inc:

THOMSON REUTERS
·
05 Nov 2024

Aquestive Therapeutics, Inc. Q3 Revenue USD 13.542 Million VS. Ibes Estimate USD 12.7 Million

THOMSON REUTERS
·
05 Nov 2024

Aquestive Therapeutics Q3 2024 Earnings Preview

seekingalpha
·
04 Nov 2024